Family Medicine · Newport News, VA
NPI
1982641171
Since 2006
Specialty
Family Medicine
Code 207Q00000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
704 Thimble Shoals Blvd, Suite 700
Newport News, VA, 23606
Phone (757) 873-2000
Groups this clinician bills Medicare through
Medicare paid, 2024
$394K
23,539 services
Medicare patients, 2024
682
Average age 75
Drug cost, 2024
$1.7M
13,381 prescriptions
Company payments, 2025
$2,893
From 36 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Thomas N Robeson was code J0897 (injection, denosumab, 1 mg), 6,120 times for 60 patients. In total Thomas N Robeson billed 23,539 services in 82 codes, and Medicare paid $394K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-07-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 6,120 | 60 | $19.95 | $122K |
| J1306 Injection, inclisiran, 1 mg | Office | 5,680 | 12 | $9.44 | $54K |
| 99213 Office E&M - Established | Office | 1,193 | 583 | $31.21 | $37K |
| 81003 Clinical Chemistry | Office | 492 | 423 | $2.20 | $1,080 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 427 | 427 | $41.04 | $18K |
| 99214 Office E&M - Established | Office | 292 | 218 | $35.30 | $10K |
| 96372 Injection Administration | Office | 223 | 87 | $10.33 | $2,304 |
| G0008 Administration of influenza virus vaccine | Office | 209 | 207 | $31.23 | $6,527 |
| 90662 Vaccine Product | Office | 204 | 203 | $81.08 | $17K |
| 91304 Vaccine Product | Office | 94 | 91 | $154.68 | $15K |
| 90480 Vaccine Administration | Office | 93 | 90 | $40.82 | $3,797 |
| 77080 Standard X-ray | Office | 92 | 92 | $37.50 | $3,450 |
| G0009 Administration of pneumococcal vaccine | Office | 80 | 80 | $29.43 | $2,354 |
| 82044 Clinical Chemistry | Office | 64 | 64 | $6.11 | $391 |
| 90677 Vaccine Product | Office | 44 | 44 | $288.53 | $13K |
By year: 2022 $316K for 14,225 services; 2023 $407K for 23,908 services; 2024 $394K for 23,539 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 492 | 423 | $2.20 | $1,080 |
| 82044 Clinical Chemistry | 64 | 64 | $6.11 | $391 |
| 87637 Infectious Agent Detection by DNA/RNA | 27 | 25 | $139.78 | $3,774 |
| 0241U Infectious Agent Detection by DNA/RNA | 16 | 16 | $131.92 | $2,111 |
Medicare prescription drug claims, 2024
In 2024, the drug Thomas N Robeson prescribed most often to Medicare patients was Atorvastatin Calcium, with 856 prescriptions and refills. In total Thomas N Robeson wrote 13,381 Medicare prescriptions that cost $1.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 856 | 2,405 | 237 | $6,263 |
| Rosuvastatin Calcium Generic | 532 | 1,469 | 149 | $6,226 |
| Levothyroxine Sodium Generic | 424 | 1,142 | 110 | $5,200 |
| Ezetimibe Generic | 372 | 1,035 | 109 | $7,971 |
| Amlodipine Besylate Generic | 316 | 864 | 88 | $1,820 |
| Gabapentin Generic | 264 | 425 | 72 | $2,993 |
| Metformin Hcl Generic | 236 | 662 | 67 | $1,109 |
| Lorazepam Generic | 219 | 241 | 49 | $830 |
| Omeprazole Generic | 202 | 588 | 61 | $1,902 |
| Losartan Potassium Generic | 197 | 521 | 50 | $1,785 |
| Hydrochlorothiazide Generic | 192 | 527 | 57 | $442 |
| Metoprolol Succinate Generic | 178 | 494 | 55 | $1,698 |
| Alprazolam Generic | 161 | 175 | 31 | $610 |
| Pioglitazone Hcl Generic | 159 | 440 | 42 | $1,592 |
| Valsartan Generic | 159 | 410 | 42 | $3,087 |
Brand drugs: 2,227 claims; generic drugs: 11,049 claims; opioid claims: 499.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Thomas N Robeson $2,893 ($2,893 in general payments such as food, travel and fees) from 36 companies. The largest payer was Abbvie Inc. with $261.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 20 | $261 |
| Axsome Therapeutics, Inc. AXSM | 15 | $255 |
| Pfizer Inc. PFE | 19 | $235 |
| Eisai Inc. 4523.T | 4 | $213 |
| Novo Nordisk Inc NVO | 7 | $211 |
| GlaxoSmithKline, LLC. GSK | 9 | $185 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 7 | $146 |
| Lilly USA, LLC LLY | 7 | $145 |
| Amgen Inc. AMGN | 13 | $135 |
| Novartis Pharmaceuticals Corporation NVS | 6 | $121 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.